Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Status: Unknown

Conditions: Serious Infection

Treatments: Drug: Ceftolozane/tazobactam

Study type: Observational

Funder types: Other

Identifiers

NCT04257812

FIS-CEF-2019-01

Details and patient eligibility

About

The aim of this study is to determine the Ceftolozane-Tazobactam Plasmatic Levels and and analyse the clinical impact that might have the dose regimens that have been used until now.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients older than 18 years old.
• Hospitalised for a serious illness.
• Treated with Ceftolozane-Tazobactam
• Patients that signed the Informed Consent.

Exclusion criteria

• Allergic to any component of Ceftolozane-Tazobactam.
• Any surgical or medical evidence that according to the investigator could interfere with the pharmacodynamics of the medication: absorption, distribution, metabolism or excretion.
• Concomitant terminal illness.
• Unable to sign the Informed Consent.

Trial design

20 participants in 1 patient group

Ceftolozane-Tazobactam cohort

Description:

Patients older than 18 years old that are hospitalised in the Virgen Macarena University Hospital that are being treated with Ceftolozane-Tazobactam in empiric or targeted treatment.

Treatment:

Drug: Ceftolozane/tazobactam